Related Experiment Video

Updated: Apr 28, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

[Endocrine therapy resistance in metastatic breast cancer: mechanisms and clinical implications]

A Orcurto, R Odermatt, A Stravodimou

    Revue Medicale Suisse
    |June 20, 2014
    PubMed

    Insights

    Endocrine therapy is key for metastatic breast cancer, but resistance is a challenge. mTOR inhibition with everolimus shows promise but increases severe side effects, necessitating careful management.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Endocrine therapy is a primary treatment for hormone-sensitive metastatic breast cancer.
    • Acquired resistance to endocrine therapy presents a significant clinical challenge.

    Purpose of the Study:

    • To explore therapeutic strategies for overcoming endocrine resistance in metastatic breast cancer.
    • To evaluate the role of mTOR inhibition, specifically everolimus, in combination with endocrine therapy.

    Main Methods:

    • Review of randomized trials investigating everolimus and endocrine therapy.
    • Analysis of efficacy and safety data from clinical studies.

    Main Results:

    • Everolimus demonstrated efficacy when combined with endocrine therapy in metastatic breast cancer.
    • The addition of everolimus significantly increased the incidence of severe side effects.

    Conclusions:

    • Understanding resistance mechanisms is crucial for developing novel breast cancer therapies.
    • Managing severe side effects associated with everolimus is essential for optimizing treatment toxicity.

    More Related Videos

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

    Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

    Published on: December 9, 2015

    12.8K
    A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer07:35

    A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

    Published on: December 26, 2016

    43.7K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    2.6K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.1K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    3.8K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    5.7K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    6.3K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.0K